Grape King Bio Ltd (TPE:1707)

Market Cap	20.52B
Revenue (ttm)	11.16B
Net Income (ttm)	1.45B
Shares Out	148.14M
EPS (ttm)	9.71
PE Ratio	14.26
Forward PE	12.75
Dividend	6.90 (5.00%)
Ex-Dividend Date	Jun 23, 2025

Volume	81,332
Average Volume	159,459
Open	138.00
Previous Close	138.00
Day's Range	137.50 - 139.00
52-Week Range	127.00 - 163.50
Beta	0.48
RSI	53.55
Earnings Date	May 9, 2025

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.